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Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei is a severe infection in the middle east,
resulting in nearly 100% mortality despite the application of combined surgical and antifungal therapy and
occurring occasionally in otherwise healthy patients. We report the first case of brain infection in a middle-
aged male in India, where R. mackenziei is not endemic.
CASE REPORT
A 50-year-old Indian male who had had type II diabetes
mellitus for the last 4 years and suffered from psychiatric illness
was admitted to the Department of Neurology, People’s Col-
lege of Medical Sciences, Bhopal, India, and presented with a
1-day history of frontal headache, dizziness, slurred speech,
and weakness over the left half of his body. Ten days previ-
ously, he had become inattentive due to his uncontrolled diet
and irregular antidiabetic treatment. The first computed to-
mography (CT) scan of the brain demonstrated a mass lesion,
and the patient underwent indigenous (Ayurvedic) treatment
for 5 to 6 days. The chest X ray was normal. Full laboratory
blood analysis revealed a hemoglobin level of 16.8 g/dl; white
blood cells, serum electrolytes, and liver function test results
were within normal ranges. Blood cultures were sterile, and
urine cultures became positive with Escherichia coli. Later, a
second CT scan revealed a large (5- to 6-cm-diameter), dis-
crete, irregular, peripheral ring-enhancing necrotic lesion in
the right frontoparietal region causing significant mass effects
and midline shift with perifocal edema (Fig. 1A and B). Neu-
rosurgical intervention consisted of a right frontoparietal cra-
niotomy for decompression of the space-occupying lesion. The
necrotic material was encapsulated, and approximately 8 ml of
thick viscous black fluid, which was predominately caseous, was
aspirated. The material was analyzed by two mycological and
histopathological laboratories. Multiple lesions were ring en-
hancing, greyish white, and soft, measuring 1.5 by 0.4 cm.
Microscopic examination of biopsy sections (pus or necrotic
tissue) stained with hematoxylin and eosin revealed necrosis
with dense and diffuse mixed inflammatory infiltrates. There
were several foreign bodies and Langhans giant cells, with
granuloma formation and the presence of numerous septate
hyphae surrounded by a dense inflammatory response (Fig. 2A
and B). Following this examination, the biopsy specimens were
also stained with Ziehl-Neelsen stain, which revealed many
moniliform septated hyphal elements (Fig. 2C). The tentative
diagnosis of chronic granulomatous inflammation with fungal
infection was made. The clinical specimens were cultured for
up to 10 days on Sabouraud dextrose agar (SDA; Difco) and
SDA supplemented with chloramphenicol (0.5 mg/ml) at 30 to
35°C, as well as on brain heart infusion agar with 5% sheep
blood (Oxoid Ltd., Basingstoke, Hampshire, England) at 37°C.
Growth of melanized fungi after 1 week was observed, and
these fungi were morphologically classified as Rhinocladiella
mackenziei (formerly Ramichloridium mackenziei). Stock cul-
tures were maintained on slants of 2% malt extract agar
(MEA; Difco) and oatmeal agar (Difco) at 30°C, and a
voucher strain was deposited into the CBS-KNAW culture
collection and preserved as CBS 125089. Microscopic studies
using slide culture techniques with potato dextrose agar were
conducted. This medium was selected because it readily in-
duces sporulation and suppresses growth of aerial hyphae (10).
After 2 weeks, slides were prepared from these cultures in
lactic acid or lactophenol cotton blue under biosafety level 3
regulations, and light micrographs were taken using a Nikon
Eclipse 80i microscope with a Nikon digital sight DS-Fi1 cam-
era. After 2 weeks of growth at 27°C on MEA in darkness, the
moderately rapidly growing colonies were velvety and oliva-
ceous brown; the reverse side was olivaceous black (Fig. 3A).
Conidiophores arose at right angles from creeping hyphae and
were stout, thick walled, brown, and 3.0 to 4.5 m wide, with
apical cells 10 to 25 m long, short cylindrical denticles, and
brown conidia which were ellipsoidal, measuring 8.5 to 12.0 by
4 to 5 m, with prominent, 1-m-wide basal scars (Fig. 3B and
C). Cardinal growth temperatures for strain CBS 125089 were
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between 9 and 40°C, with an optimum at 30°C and some
growth still occurring at 40°C. Morphologically, R. mackenziei
resembles Pleurothecium obovoideum (Mats.) Arzanlou and
Crous from dead wood, but P. obovoideum has distinct conid-
iophores and the ascending hyphae are thick walled, with cy-
lindrical denticles up to 1.5 m long. In contrast, R. mackenziei
has only slightly prominent denticles. P. obovoideum clusters in
the order Chaetosphaeriales (3).
DNA was extracted using an ultraclean microbial DNA iso-
lation kit according to the instructions of the manufacturer
(Mo Bio, Carlsbad, CA). Internal transcribed spacer (ITS)
ribosomal DNA was amplified using primers V9G (5-TTA
CGT CCC TGC CCT TTG TA-3) and LS266 (5-GCAT TCC
CAAACA ACT CGA CTC-3) and sequenced with the inter-
nal primers ITS1 (5-TCC GTA GGT GAA CCT GCG G-3)
and ITS4 (5-TCC TCC GCT TAT TGA TAT GC-3). PCR
amplification and sequencing were performed according to the
methods of Badali et al. (4). Sequences were compared with
entries in GenBank and, by using local blast searching, with
entries in a molecular database maintained for research pur-
poses at the CBS-KNAW Fungal Biodiversity Centre, Utrecht,
The Netherlands. The isolate (CBS 125089) was identified as
R. mackenziei, having 99.5% sequence identity to the ex-type
isolate of that species (CBS 650.93; accession no. AY857540),
which had originally been isolated from a patient in Saudi
Arabia with cerebral phaeohyphomycosis. The molecular re-
sults confirmed the mycological diagnosis, and histopatholog-
ical observation led to the diagnosis of cerebral phaeohypho-
mycosis due to R. mackenziei.
For the management of the case, insulin infusion was given
along with intravenous amphotericin B deoxycholate (0.6
mg/kg of body weight/day). Simultaneously, empirical antitu-
berculous and antibacterial therapy, consisting of sequential
beta-lactam antibiotics (ceftriaxone, piperacillin, and cefopera-
zone) combined with metronidazole and amikacin, was started.
During follow-up, there was no clinical improvement. There-
fore, successive CT scans were obtained after 8 days, showing
a decrease in the lesion size (to around 4 cm); however, an
increase in parietal edema, enlargement of mass effects, and
multiple, coalescing, ring-enhancing cerebral lesions were seen
(Fig. 1C). Despite amphotericin B therapy, the patient’s con-
dition continued to deteriorate, and he expired 2 weeks after
diagnosis of the disease. The in vitro antifungal susceptibilities
of this strain (CBS 125089) were determined by broth microdi-
lution according to the guidelines in Clinical and Laboratory
Standards Institute document M38–A2 (9). Methods for
sporulation and preparation of suspensions were according to
Badali et al. (5). Paecilomyces variotii (ATCC 22319), Candida
FIG. 1. (A and B) Initial CT scans showing a discrete, large (approximately 5- to 6-cm-diameter), irregular, peripheral ring-enhancing necrotic
mass lesion in the right frontoparietal region with mass effects and midline shift with perifocal edema. (C) Third CT scan showing a decrease in
lesion size (to around 4 cm) but increasing parietal edema, enlargement of mass effects, and multiple, coalescing, ring-enhancing cerebral lesions.
FIG. 2. (A and B) Hematoxylin and eosin staining revealed necrosis with dense and diffuse mixed inflammatory infiltrates, granuloma
formation, and the presence of numerous septate hyphae (arrows) surrounded by a dense inflammatory response. (C) Biopsy specimens were also
stained with Ziehl-Neelsen stain, which revealed many moniliform, branched, septated hyphal elements.
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parapsilosis (ATCC 22019), and Candida krusei (ATCC 6258)
were used as quality control organisms (9). The MICs of an-
tifungal drugs were as follows: amphotericin B, 16 g/ml; flu-
conazole, 32 g/ml; itraconazole, 0.063 g/ml; voriconazole,
0.5 g/ml; posaconazole, 0.031 g/ml; and isavuconazole, 0.5
g/ml. The minimum effective concentrations of the two echi-
nocandin agents caspofungin and anidulafungin were 8 and 4
g/ml, respectively.
Discussion. Cerebral phaeohyphomycosis caused by mela-
nized fungi is a rare but highly significant disease due to the
regional prevalence and high mortality of up to 70% despite
combined surgical and antifungal therapy (11). Previously, the
majority of reported central nervous system (CNS) infections
caused by dematiaceous fungi were found to be brain abscesses
in patients with no predisposing factors or immunodeficiency;
symptoms included headache, seizures, cerebral irritation, fe-
ver, and neurological deficits (13). Binford et al. (6) described
one of the first cases of brain abscess due to Cladosporium
trichoides (Cladophialophora bantiana), and Campbell and Al-
Hedaithy (7) reported similar cases caused by R. mackenziei.
The latter review listed eight cases of this type of infection,
all occurring in countries of the middle east. Exophiala derma-
titidis (8), Cladophialophora bantiana (12), and R. mackenziei
(7, 16), all members of the order Chaetothyriales, are notorious
agents of cerebral infections. One of the most striking features
of these organisms is their neurotropism in humans.
Arzanlou et al. studied the phylogenetic and morphotaxo-
nomic revision of the genus Ramichloridium and allied genera,
because Rhinocladiella was in the past frequently confused with
the genus Ramichloridium. Rhinocladiella species were shown
to cluster in the Chaetothyriales, while Ramichloridium species
cluster in the order Capnodiales (3).
R. mackenziei affects only the CNS and the integuments,
with nearly 100% mortality in both immunocompetent and
immunocompromised individuals.
This species is the most common agent of brain infection
and was thought to be restricted to the middle east and the
Persian Gulf region (7). Cases identified in the United King-
dom or the United States concerned immigrants from Saudi
Arabia and Kuwait (16). Until now, R. mackenziei has never
been isolated from the environment. The natural niche of this
organism thus remains unknown. To the best of our knowl-
edge, this patient represents the first case of R. mackenziei
infection outside the arid climate zone of the middle east. In
contrast to the strains involved in all cases reported thus far,
this strain (CBS 125089) originated from a humid subtropical
climate, infecting a patient who claimed he had never traveled
outside India.
Cerebral infections due to R. mackenziei have thus far been
diagnosed after CT-guided needle aspiration and were proven
by positive histopathology and culture results. The mortality is
almost 100% for all reported cases of infection, despite surgi-
cal resection and antifungal therapy. There is no standard
therapy for this disease. Treatment as presented in the litera-
ture has involved mostly (high-dose lipid) amphotericin B,
itraconazole, and flucytosine or a combination of these drugs
(14). However, strains of R. mackenziei isolated from infected
patients are in vitro resistant to amphotericin B, which is often
used as the gold standard of treatment. Only a single patient is
reported to have survived an R. mackenziei cerebral infection,
with pronounced radiological and clinical improvement after
switching therapy from a combination of liposomal amphoter-
icin B, flucytosine, and itraconazole to posaconazole (2). This
account is supported by in vitro results and data from a murine
infection model (1), in which posaconazole prolonged the sur-
vival of mice and reduced the brain fungal burdens compared
to the survival of and burdens in mice treated with itraconazole
and amphotericin B.
Previous in vitro antifungal susceptibility testing of 10 strains
of R. mackenziei (5) has shown that the widest range of MICs
(2 to 16 g/ml) and the highest MICs (MIC50, 8 g/ml, and
MIC90, 16 g/ml) were those of amphotericin B. In contrast,
quite uniform patterns of susceptibility to itraconazole,
posaconazole, and isavuconazole were obtained. Our results
were in line with animal test data, but clinical experience and
animal experiments with the newer antifungal drugs have not
been reported. Animal studies have suggested that no benefit
from amphotericin B is achieved in experimental infection due
to poor penetration into the CNS (1). Although liposomal
amphotericin B likely has better CNS penetration, liposomal
amphotericin therapy failed for the only patient reported to
have survived an R. mackenziei cerebral infection (2), who
improved only on posaconazole, an agent with good CNS pen-
etration (15) and a low MIC for the pathogen (2) Delay in
FIG. 3. R. mackenziei (CBS 125089). (A) Colony on MEA (Difco) at 30°C after 2 weeks in darkness. (B and C) Semimicronematous
conidiophores and sympodially proliferating conidiogenous cells (arrow). Scale bars, 10 m.
648 CASE REPORTS J. CLIN. MICROBIOL.
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
diagnosis, misidentification, poor standard therapy, and lim-
ited data on effective alternative drugs are the main factors
promoting the development of cerebral phaeohyphomycosis.
With early diagnosis, when the lesion is singular, and with
effective therapy including complete surgical excision of brain
abscesses, the patient’s outcome may be improved.
Brain abscesses incited by R. mackenziei in patients from
areas where the fungus is not endemic have not been reported
previously. Now that the fungus has been observed outside its
area of endemicity, R. mackenziei, along with other neurotropic
agents, should always be considered a potential etiologic agent
of cerebral phaeohyphomycosis in all patients, regardless of
their area of residence.
Nucleotide sequence accession number. The sequence from
isolate CBS 125089 determined in this study has been depos-
ited in GenBank under accession number GQ863214.
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